AKT1 and metabolic dysfunction-associated steatohepatitis: Future studies should investigate 2-HOBA efficacy in both sexes, evaluate 2-HOBA treatment after the onset of clinical MASH to determine its therapeutic value, and further explore the molecular mechanisms underlying 2-HOBA’s effects, particularly its impact on AKT/GSK3β signaling in liver tissue.